PT-141 peptide dosage chart explained: approved bremelanotide dose is 1.75 mg injected subcutaneously 45 minutes before activity, up to eight times monthly.
PT-141 (bremelanotide) is dosed at 1.75 mg subcutaneously about 45 minutes before sexual activity for the FDA-approved product Vyleesi. The maximum frequency is one dose in 24 hours and no more than eight doses per month. Off-label nasal spray and injection protocols vary widely, so a pt-141 peptide dosage chart helps compare published ranges safely.
What Is PT-141 and How Does It Work?
PT-141 is a synthetic peptide that activates melanocortin receptors, primarily MC4R, in the brain. It is approved for hypoactive sexual desire disorder (HSDD) in premenopausal women. Unlike PDE5 inhibitors such as sildenafil, PT-141 does not act directly on blood vessels in the genitals. Instead, it works through the central nervous system to influence sexual desire.
Many people search for a pt 141 peptide dosage chart because the drug is used off-label for libido in men and women. The approved pt 141 peptide dosage is fixed at 1.75 mg, but off-label protocols may adjust the amount based on the route of administration and individual response.
FDA-Approved PT-141 Dosing at a Glance
| Parameter | Approved Dosing |
|---|---|
| Route | Subcutaneous injection |
| Single dose | 1.75 mg |
| Timing | 45 minutes before sexual activity |
| Maximum frequency | Once per 24 hours |
| Monthly limit | 8 doses per month |
| Approved population | Premenopausal women with HSDD |
The FDA label does not include weight-based dose adjustments. Taking more than 1.75 mg does not improve results and increases the risk of nausea and blood pressure changes. The injection is given into the abdomen or thigh, and the site should be rotated.
Off-Label PT-141 Dosage Ranges by Route
Beyond the approved injection, researchers have studied other routes and amounts. The table below summarizes common off-label ranges found in published literature and online discussions. These are not FDA-approved and should not be considered medical advice.
| Route | Typical Off-Label Range | Notes |
|---|---|---|
| Subcutaneous injection | 1.75 mg (approved) or 1–2 mg | Most common in clinical studies; once per day maximum |
| Intranasal spray | 10–20 mg | Not FDA-approved; absorption is variable and dose is much higher |
| Sublingual or oral | Not well studied | Poor bioavailability; not recommended |
| Topical | No reliable data | Not recommended |
When researchers discuss peptide pt-141 dosage, they usually separate the approved 1.75 mg injection from much higher intranasal amounts. The difference exists because the nasal mucosa absorbs only a fraction of the drug compared with subcutaneous tissue.
PT-141 Dosage for Women
For premenopausal women with HSDD, the only FDA-approved dose is 1.75 mg subcutaneously. Phase 3 trials tested lower doses (0.75 mg and 1.25 mg) and found them less effective, while higher doses did not add benefit. A pt-141 dosage for women therefore stays at 1.75 mg when using the prescription product.
Postmenopausal women are not included in the FDA approval, but some small studies have used 1.75 mg off-label. Women should discuss cardiovascular risks with a healthcare provider before using PT-141, especially if they have high blood pressure or heart disease.
PT-141 Nasal Spray Dosage and Timing
Nasal spray PT-141 is not FDA-approved in the United States. Published studies on intranasal bremelanotide used 10 mg to 20 mg, typically 45 minutes before sexual activity. One study found that 20 mg improved sexual desire but caused more nausea than lower amounts. The pt 141 peptide spray dosage is therefore much higher than the injectable dose because nasal absorption is limited.
Because nasal sprays sold online are unregulated, their actual peptide content and purity can vary. Users cannot rely on a label to confirm the exact amount. This makes nasal PT-141 riskier than the prescription injection.
Timing, Frequency, and Side Effects
- Timing: Inject 45 minutes before activity. Effects may begin in 30 minutes and last up to 3 hours.
- Frequency: Do not exceed one dose in 24 hours or eight doses per month.
- Common side effects: Nausea (reported in about 40% of users), flushing, headache, and injection site reactions.
- Blood pressure: PT-141 can cause a temporary rise in blood pressure. It is contraindicated in people with uncontrolled hypertension or known cardiovascular disease.
- Alcohol: Limit alcohol, as it may worsen blood pressure effects.
Legal Status and Safety Considerations
PT-141 is a prescription medication in the US. The injectable form (Vyleesi) is approved only for premenopausal women with HSDD. Any other use, including nasal spray, off-label male use, or research-grade peptide purchases, is not FDA-approved. Research-grade peptides are not intended for human consumption and may contain impurities.
Anyone considering PT-141 should consult a healthcare professional. A clinician can review medical history, medications, and cardiovascular risk. Self-dosing from an online chart can lead to side effects without monitoring.
Key Takeaways
- FDA-approved PT-141 dose: 1.75 mg subcutaneously 45 minutes before activity.
- Maximum frequency: once per 24 hours, no more than 8 times per month.
- Nasal spray doses in studies: 10–20 mg, but not FDA-approved.
- PT-141 is not approved for men or for postmenopausal women.
- Side effects include nausea, flushing, headache, and blood pressure increases.
Frequently Asked Questions
What is the standard PT-141 dosage?
For the FDA-approved injectable (Vyleesi), the standard dose is 1.75 mg subcutaneously at least 45 minutes before sexual activity. It should not be used more than once in 24 hours or more than eight times per month. Off-label nasal spray doses are much higher, typically 10–20 mg, but they are not FDA-approved.
How long does PT-141 take to work and how long do effects last?
PT-141 usually starts working within 30 to 60 minutes after injection. Effects can last up to 3 hours. It is taken as needed, not on a daily schedule.
Is PT-141 approved for men?
No, PT-141 is not FDA-approved for men. Some clinical studies have explored off-label use for erectile dysfunction and low libido in men, often using 1.75–2 mg subcutaneously or 10–20 mg intranasally. A healthcare provider should supervise any off-label use.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.